AmgenNASDAQ: AMGN

AMGN has exceeded expectations for its earnings in the third quarter and has met sales predictions. The company has slightly increased its sales forecast for 2024 but has narrowed the range for earnings per share (EPS).

Amgen Inc. (NASDAQ:AMGN) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 4:30 PM ET. The call will feature company leaders, including CEO Robert Bradway and other executives, as well as analysts from various financial institutions. The conference facilitator, Julianne, will manage the call and has muted all lines to minimize background noise.

Amgen (AMGN) reported quarterly earnings of $5.58 per share, which is higher than the Zacks Consensus Estimate of $5.11 per share. This is an increase compared to last year's earnings of $4.96 per share.

There are other reasons to invest in these stocks besides just the dividends.

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) has announced that its Board of Directors has approved a dividend of $2.25 per share for the fourth quarter of 2024.

In addition to Wall Street's predictions for Amgen's (AMGN) earnings, take a look at forecasts for some important metrics to better understand how the company performed in the quarter that ended in September 2024.

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) has announced that it will share its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, after the U.S. markets close.

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included the report titled "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" in its collection. This report offers essential details about approved medications and those under research as biosimilar antibodies for Prolia and Xgeva (denosumab). The report includes:

Amgen (AMGN) lacks the necessary mix of two important factors that could lead to a strong earnings report in the near future. Be ready for the main expectations.